When a transformation takes place in a field of science, rarely is the cause singular. Such is true in toxicology, where a constellation of regulatory, scientific, and public/social changes are coming together to spearhead a real shift in practice. Animals, principally rodents, have long been the mainstay for testing the toxicity of commercial chemicals, pesticides, pharmaceuticals, and other substances. Since the 1920s, animals have been used to test the safety of new chemicals (including those in cosmetics) as well as drugs and vaccines. But now a "sea change" is taking place as a highlevel initiative in the US and powerful new legislation in Europe are pushing in vitro alternatives to the foreground.
"Toxicology is becoming a real science," says Alan Goldberg, director of the Center for Alternatives to Animal Testing at Johns Hopkins University in Baltimore, MD. "It is moving from largely an observational enterprise to a science based on biological pathways, cellular mechanisms, and the chemical understanding of molecular systems." Such advancement has its roots in pragmatism. Officials at the National Toxicology Program (NTP) and the Environmental Protection Agency (EPA) are facing an intractable problem. They have to assure the safety of at least 2000 new compounds each year-in addition to the 80,000 already in commerce. Yet, the agencies can only manage to test several hundred annually at a cost of roughly $1-2 million per compound.
The issue has become more urgent with a March 2008 report by John Stephenson, director of Natural Resources and Environment with the Government Accountability Office (GAO). The report reviews the EPA's efforts to control the risks of new and existing chemicals under the outdated Toxic Substances Control Act, unchanged since 1976, and finds those efforts lacking. Among other problems, the report notes that the EPA lacks the authority to require companies to safety test their own chemicals and criticizes the animal models as often inaccurate or unable to predict ultimate toxicity in humans.
For example, the gold standard of toxicology, called acute toxicity testing, is far from perfect. Typically, scientists give animals one dose of a test chemical, administered for not more than 24 hr, and then count the number that have died 14 days later; that number is recorded and plotted as the lethal dose for 50% of the animals or LD50. The idea is to identify doses that cause no adverse effects versus those that cause life-threatening toxicity. Despite the time, cost, and potential waste of such testing practices, an estimated 35% of pharmaceutical compounds tested in animals historically have failed in human clinical trials because of toxicity problems. "Rodent models are imperfect instruments, at best, and very expensive," says chemical biologist Christopher Austin, director of the Chemical Genomics Center (NCGC) at the National Institutes of Health (NIH) in Bethesda, MD. "Combined with the increasing public unease with using animals for toxicology, it was just obvious to a number of us that we should try a new way."
On the public front, that way is a new piece of legislation, "The Kid Safe Chemicals Act," introduced on May 20 this year by US Senator Frank R. Lautenberg, a New Jersey Democrat, along with two other members of the US Congress. The legislation would require chemical manufacturers to provide health and safety information on everyday chemicals instead of presuming a substance is safe until proven dangerous.
From a research perspective, the attempt to procure that heath and safety information happened in 2005, when the newly formed NCGC joined forces with the National Human Genome Research Institute (NHGRI), the NTP/National Institute of Environmental Health Sciences (NIEHS), and the EPA. The NIH had established the NCGC in 2004 to provide academic investigators with a highthroughput screening and chemical probe capacity previously available only in the pharmaceutical industry. With that capacity in mind, the NHGRI/NTP/EPA collaborators were thrilled when the National Academy of Sciences (NAS) came out with a report about the future of toxicology (http://www.nap.edu/catalog.php?record_ id=11970). The NAS vision recognized the importance of new technologies, including high-throughput screening, in the field of toxicology and recommended the integration of so-called "toxicogenomics" into regulatory decision making. In response to the report, the NCGC-NTP-EPA triumvirate published a memorandum of understanding (http://www.genome.gov/ Pages/ Newsroom/CurrentNewsReleases/ ntpncgcepamou121307FinalV2.pdf) in which they committed to implement the NAS vision. The EPA would provide chemicals for testing and computational expertise; the NTP would offer its knowledge of toxicology and a database of compounds; and, crucially, the NCGC would offer highthroughput cell-based screening of new chemicals. The NAS report "gave a thirdparty independent validation to exactly the approach our collaboration was taking," says NCGC's Austin.
Thus far, the collaboration has screened 3000 chemicals in over 50 high-throughput cell-based screening assays. In a paper published earlier this year in Environmental Health Perspectives, the group established "proof of principle." They compared
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results using cells of the same type but derived from different species-for example, kidney cells from rat and human. The key finding was what cell biologists have long known: a rodent is not a mini-human. For example, in a cell viability assay based upon the enzyme luciferase, coupled to ATP quantification, researchers found that the overall activity profiles of substances tested in human SH-SY5Y neuroblastoma cells differed markedly from those in mouse N2a neuroblastoma cells. In addition, the researchers found that test chemicals often behave very differently in human cell types thought to be closely related to each other. Overall, 39 tested compounds showed significant differences depending on the species, with 34 having greater potency in rodent cells and 5 being more toxic to human cells. "This paper shows that we can generate reliable reproducible data based on high-throughput techniques," Austin says. "It also gives you a really tantalizing view of both the promise and complexity of our approach."
The European Perspective Meanwhile, European scientists and regulatory agencies are facing similar pressures to update their toxicity testing guidelines. As with the situation in the US, one of the biggest incentives is cost. Animal tests in Europe consume roughly 3 billion euros per year, and it takes ~150,000 animals to test one new chemical to current regulatory guidelines. Added to that are the 30,000 existing commercial chemicals of which 86% lack full toxicology data. European scientists have calculated that it would take 67 million animals if regulators were to treat the 30,000 high-priority substances like new chemicals, with still another 110,000 lower-priority chemicals possibly to be tested in the future. Added to the enormous cost of using animals in toxicity testing is tough European Commission (EC) legislation-the Because there are an estimated 140,000 existing chemicals in Europe, the agency is now prioritizing, based on which substances are produced in the highest volumes. The top 30,000 will be evaluated for toxicity and results posted in a public database (http://echa.europa.eu/home_en.asp). Such regulatory urgency is spurring the development of alternatives to animal testing both in academic and commercial laboratories.
To assist in these efforts, the European Union (EU) is now spending 25 million euros each year to fund a mixed consortia of up to 30 partners, most from academia but some from large cosmetic, chemical, and pharmaceutical companies. In addition, there are some incentives to get more small/ medium enterprises involved. Once new cell-based in vitro assays are developed they are validated by the European Centre for Validation of Alternative Methods (ECVAM) in Ispra, Italy. ECVAM compares each new in vitro assay developed with the standard animal model and makes sure that the new test is comparable or better. Similar organizations exist elsewhere, including the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) in the US and the Japanese Center for the Validation of Alternative Methods (JaCVAM) in Japan. As ethical, regulatory, and proprietary interests are now intersecting, the quest for in vitro alternatives has become a "win-win situation," says Thomas Hartung, former head of ECVAM and current head of the EC's Unit for Traceability, Risk and Vulnerability Assessment. "In the end, everybody wants to have validated alternative tests available," he says.
"Industry is coming up with procedures that we can use and they are very happily applying our assays that have been validated."
But the validation process is lengthy (2-8 years), cumbersome, and costly (~$300,000 per test). And validation by ECVAM is not the last step. ECVAM must present its validated tests to OECD (Organization for Economic Cooperation and Development). Although not an "organization" per se, the OECD offers a discussion forum for its 30 full member countries, including the US. The OECD in 1981 passed the Mutual Acceptance of Data Act, which states that all member states must accept ultimate OECD test guidelines. Thus, a substance tested in, say, France automatically complies with the standards of Austria. The result was a streamlined efficiency in toxicity testing because different countries did not have to perform duplicate testing in order to market products throughout Europe. But the law also caused a major setback because test guidelines decided 30 years ago have become "frozen in time," says Hartung. That's because all OECD countries must agree to any change. For example, the controversial Draize Test developed in 1944-in which a test substance is applied to the eye or skin of an animal (usually an albino rabbit) and the level of irritation monitoredis still performed today, albeit with some modifications and on reduced numbers of animals.
Given such constraints, ECVAM thus far has validated and approved at the OECD level only three in vitro cell-based assays (for skin corrosion and phototoxicity) that fully replace animals for testing. In the skin corrosion in vitro assay, scientists apply the test chemical to an "epidermis" in culture reconstructed from multiple layers of human keratinocytes under a functional layer of corneal cells. Next, researchers test cell viability at specified exposures to the chemical with the dye MTT. In another validated test, researchers create discs of rat skin and apply a test substance to the inner epithelium. Researchers then measure potential corrosiveness based on the skin's resistance to an electrical current passed across the disc; they test penetration of the chemical based on movement of the dye sulforhodamine. Finally, Cell 134, August 22, 2008 ©2008 Elsevier Inc. 559 scientists can measure phototoxicity with a test called 3T3 NRU PT, in which researchers expose a mouse fibroblast cell line to the chemical and compare cytotoxicity (as measured by the cell's ability to take up a vital dye called neutral red) with and without exposure to UVA under carefully defined conditions. Other cell-based assays have been accepted or are under discussion to either fully replace animals or reduce the number used.
Back to the Petri Dish As these new in vitro tests feed into the alternative cell-based assay pipeline, they reveal a healthy growth in the basic science of toxicology. Researchers are successfully creating sophisticated tissue, cellular, and high-throughput assays, as well as computer modeling to measure and predict the effects of various substances on overall physiology. For example, researchers have been able to create and commercialize artificial human skin equivalents derived from cultured human cells. Researchers at MatTek in Ashland, MA have created models such as tracheal/bronchial epithelium and four types of vaginal tissues derived from human epithelial and dendritic cells. Scientists at SkinEthic in Nice, France have created their EpiSkin model by culturing adult human keratinocytes (from plastic surgery donors) on a collagen base under conditions that allow the terminal differentiation of cells and the reconstruction of a functional epidermis. Finally, investigators at Phenion in Duesseldorf, Germany have developed a full thickness skin model based on biopsy material from healthy human donors. Researchers culture the mix of epidermal and dermal cells in a stable matrix that does not contract under physiological forces in order to cultivate a structure similar to the dermis and then overlay keratinocytes to form the epidermis.
According to Klaus Schroeder, head of development at Phenion, there is an enormous demand for these new cellbased assays. For example, scientists currently use two primary in vitro assays to screen cosmetic ingredients: cultures of mammalian epidermal cells and a bacterial mutagenesis assay called the Ames test. Both produce a high number of false positives, says Schroeder. A positive result means the ingredient immediately has to be tested in whole animals. "There is a link missing between simple cell culture and the whole animal," says Schroeder. "This link could be an artificial skin equivalent."
Representatives from the cosmetic industry agree. They are faced with an enormous dilemma. How can they meet the 2009 and 2013 deadlines for EC legislation while currently lacking the requisite in vitro alternatives? The answer is to band together. Cosmetic, toiletry, and perfume companies are now working through Colipa, a European Trade Association, to help ECVAM speed the validation of new in vitro tests. New assays are being developed everywhere-from academia, to start-up biotech companies, to in-house research laboratories at cosmetic giants such as tissue engineering facilities built by L'Oreal in Lyon and Nice, France as well as in China. In 2006, a subsidiary of L'Oreal called EpiSkin acquired SkinEthic. In April 2007, ECVAM announced the validation of the SkinEthic epidermis-on-collagen assay as a full replacement method for chemical testing in animals. In addition, L'Oreal has partnered with an information technology start-up called Solidus in Troy, NJ. The partnership will explore using computer algorithms in conjunction with cell assays to both manage the information load of high-throughput technologies and also simulate the toxicology dynamics of a whole animal in silico.
Beyond building tissue engineering resources and partnering with biotech, perhaps the most striking shift in industry is the collaboration between the major players themselves, including L'Oreal, Proctor & Gamble, and Estee Lauder. The companies are actually putting much of their toxicology tests and data on the table. "It is not a kind of race," says Patricia Pineau, Scientific Communication Director, L'Oreal Research in Paris. "While the lack of competition seems bizarre for industry, we are really sharing." The reason is that what the industry is swapping is not information about their products but rather information about the testing of their products. What cosmetic company wants to spend money developing toxicology tests when the budget could be spent on new product innovation?
Despite this push, however, the regulatory framework remains conservative. "We are still doing the same toxicology animal experiments from 40 years ago," Hartung says. "There is a tremendous disconnect between the basic science and the regulation. There is no other area in science where this has happened so dramatically." Still, toxicology is shifting from an observational enterprise (how many animals died or developed tumors) to a more predictive science (what fingerprint of cellular responses can tell us that this substance likely causes kidney failure in a human). That is exactly what the British scientists W.M.S. Russell and R.L. Burch sought when they developed their "3 R's rule" (reducing, refining, and replacing) for chemical testing in animals nearly half a century ago. Although in vitro cellbased alternatives can reduce the number of animals being tested, can help to refine the methodologies used, and ultimately will replace animal models, what remains to be seen is not whether this will happen-but how. Clearly researchers working on the basic science of toxicology can anticipate big changes for their field, with those adept in veterinary science joining others with expertise in cell culture, robotics, and bioinformatics. "Basic researchers should think about the processes that they study from a toxicological-not a beneficialperspective," says Austin. "Think about what perturbs a process in the cell and how that could be adapted for a highthroughput screen. And then, when you've got it, call me."
